EMCDDA Home
  • EN
Search

Table TDI-3. New clients entering treatment by primary drug, 1998–2011

Part (iii) New stimulants (amphetamines and MDMA) clients by country and year of treatment (%)

Country19981999200020012002200320042005200620072008200920102011
Belgium(1)3.4::::::6.8:::13.813.712.6
Bulgaria0.00.00.00.00.20.91.52.02.72.06.73.51.02.0
Czech Republic56.852.846.047.855.055.659.060.161.763.863.063.468.069.7
Denmark:11.07.0:10.312.714.211.216.815.516.112.811.910.8
Germany::10.211.410.010.29.49.410.010.410.610.312.615.3
Estonia::::::::::4.56.410.84.9
Ireland4.85.76.59.98.68.06.75.73.84.53.42.11.6:
Greece0.00.20.30.40.70.60.70.10.40.10.60.00.10.3
Spain2.32.12.73.03.71.71.92.01.91.61.61.4:
France:1.6:::2.1:1.20.90.80.90.40.40.5
Italy(2)0.91.11.01.01.01.01.00.90.60.50.90.40.50.5
Cyprus6.16.06.25.31.43.11.30.00.62.40.5
Latvia(3)7.06.73.95.413.315.626.826.425.427.428.231.130.228.2
Lithuania3.04.82.40.04.36.64.84.32.72.0
Luxembourg(4)3.02.01.01.00.00.02.50.42.42.93.10.60.40.0
Hungary(5)14.010.77.57.06.38.27.911.09.612.211.410.911.812.2
Malta(6):::::1.20.01.65.0::1.62.31.6
Netherlands8.16.74.84.15.67.08.39.19.510.38.66.97.27.3
Austria(7)0.00.00.00.00.00.00.00.04.54.13.03.14.74.7
Poland(8)6.06.75.86.08.111.9::::28.125.426.9:
Portugal:0.00.0::0.80.50.20.40.40.30.10.30.3
Romania0.30.51.01.01.80.81.41.70.52.01.5
Slovenia(9):0.7::1.01.01.11.20.70.40.41.10.71.0
Slovakia3.22.36.87.815.125.432.130.432.633.939.134.941.042.1
Finland41.141.930.830.033.933.930.926.32424.125.319.113.412.4
Sweden(10)28.732.334.232.128.625.627.128.625.318.820.1:
United Kingdom(11)8.04.03.03.06.07.05.65.05.95.94.64.63.9:
Croatia::::::::11.210.34.54.12.72.7
Turkey::::::7.57.34.24.63.11.60.90.9
Norway::::::::::::::
 

Notes:

: Indicates data not available

(1) In Belgium if the exact primary drug is not known, the generic category is recorded. In 2010 there were 294 Opiates, 8 Cocaine, 7 Stimulants, 3 Hypnotics and Sedatives and 1 Hallucinogens clients with the primary exact drug unknown. Of which 27, 1 and 5 were new clients for respectively Opiates, Cocaine and Stimulants. 2000 data were available but they were not included due to a lack of comparability. 1998 data refers to opioids in general. 2005 data only refers to outpatient and low-threshold agencies and do not cover Brussels Capital Region.

(2) In 2010 around 29% of all clients and 30% of new clients were registered as not known / missing for the primary drug category. Caution should be made when comparing data over time.

(3) In 2010 Latvia submitted a new dataset with a more precise TDI EMCDDA definition. 2010 data in this table are still methodologically in line with the data from previous years.

(4) Data refer to all treatments.

(5) From 2003 a new, quasi compulsory treatment (diversion) became available for drug offenders (meeting the requirements) as an alternative for criminal prosecution. As these cases give the majority of clients entering treatment for the first time in their lives from 2004 and the composition of clients in diversion differs from regular clients it especially changes the composition of all clients entering treatment for the first time in their lives. The source of the data has changed in 2007: from 'Hungarian National Focal Point – National statistical programme' (1997-2006) to 'Hungarian National Focal Point – TDI data collection' (2007). The change limits the comparability of the 2007 data to previous data.

(6) In order to include time trends, data reported in Table 3 refer to one outpatient centre for which data were available for the whole time period.

(7) In the case of Austria, up to 2005 data only refer to clients in substitution treatment, using opioids as primary drug. Since 2006, data are based on new DOKLI data collection system.

(8) Data refer to all treatments up to 2002. For 2003 data refer to first treatments. For 2004-2008, data were not available and therefore not included in the analysis. Category amphetamines includes both amphetamine and methamphetamine. From 2008 data presented are from TDI pilot project. Caution should be made when interpreting.

(9) Data for 2004 includes data for outpatient clients and clients treated in prison. Data for outpatient clients was validated, however data collection for prison clients was still in the process of development, thus figures are underestimated.

(10) Data before 2000 were available but were not included because of a major change in the reporting systrem, which would have biased the comparison of data over time. The system is under development and every year new units are added to the information system. 2007 data do not cover treatment units in prisons.

(11) Data corresponds to the financial year, that is from 1st of April to 31st March of the following year. Data refer to all treatments up to 2002 and to new treatments from 2003. Before 2003, data only refer to amphetamines.

Poland:

See also ‘General notes for interpreting data’ on the Explanatory notes and help page.

Source:

Reitox national reports 2012 — Standard table 3 and TDI.

About the EMCDDA

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the reference point on drugs and drug addiction information in Europe. Inaugurated in Lisbon in 1995, it is one of the EU's decentralised agencies. Read more >>

Contact us

EMCDDA
Praça Europa 1, Cais do Sodré
1249-289 Lisbon
Portugal
Tel. (351) 211 21 02 00
Fax (351) 218 13 17 11

More contact options >>

Page last updated: Friday, 26 April 2013